AU2006322045A1 - Quinolone M1 receptor positive allosteric modulators - Google Patents
Quinolone M1 receptor positive allosteric modulators Download PDFInfo
- Publication number
- AU2006322045A1 AU2006322045A1 AU2006322045A AU2006322045A AU2006322045A1 AU 2006322045 A1 AU2006322045 A1 AU 2006322045A1 AU 2006322045 A AU2006322045 A AU 2006322045A AU 2006322045 A AU2006322045 A AU 2006322045A AU 2006322045 A1 AU2006322045 A1 AU 2006322045A1
- Authority
- AU
- Australia
- Prior art keywords
- oxo
- dihydroquinoline
- carboxylic acid
- fluoro
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04J—MULTIPLEX COMMUNICATION
- H04J3/00—Time-division multiplex systems
- H04J3/02—Details
- H04J3/06—Synchronising arrangements
- H04J3/0635—Clock or time synchronisation in a network
- H04J3/0638—Clock or time synchronisation among nodes; Internode synchronisation
- H04J3/0658—Clock or time synchronisation among packet nodes
- H04J3/0661—Clock or time synchronisation among packet nodes using timestamps
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/14—Network architectures or network communication protocols for network security for detecting or protecting against malicious traffic
- H04L63/1441—Countermeasures against malicious traffic
- H04L63/1458—Denial of Service
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/12—Applying verification of the received information
- H04L63/123—Applying verification of the received information received data contents, e.g. message integrity
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Computer Security & Cryptography (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- Computer Hardware Design (AREA)
- Computing Systems (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
- Control Of Eletrric Generators (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74223405P | 2005-12-05 | 2005-12-05 | |
| US60/742,234 | 2005-12-05 | ||
| US78927206P | 2006-04-04 | 2006-04-04 | |
| US60/789,272 | 2006-04-04 | ||
| PCT/US2006/046262 WO2007067489A1 (en) | 2005-12-05 | 2006-12-04 | Quinolone m1 receptor positive allosteric modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006322045A1 true AU2006322045A1 (en) | 2007-06-14 |
Family
ID=37963841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006322045A Abandoned AU2006322045A1 (en) | 2005-12-05 | 2006-12-04 | Quinolone M1 receptor positive allosteric modulators |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8389545B2 (https=) |
| EP (1) | EP1963271B1 (https=) |
| JP (1) | JP5192389B2 (https=) |
| AT (1) | ATE475650T1 (https=) |
| AU (1) | AU2006322045A1 (https=) |
| CA (1) | CA2631917A1 (https=) |
| DE (1) | DE602006015851D1 (https=) |
| TW (1) | TW200840814A (https=) |
| WO (2) | WO2007067489A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009542663A (ja) | 2006-06-28 | 2009-12-03 | メルク エンド カムパニー インコーポレーテッド | ベンジル置換キノロンｍ１受容体ポジティブアロステリックモジュレーター |
| AU2009206580A1 (en) * | 2008-01-25 | 2009-07-30 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| AU2009215033A1 (en) | 2008-02-15 | 2009-08-20 | Merck Sharp & Dohme Corp. | Fused pyridone M1 receptor positive allosteric modulators |
| US8173672B2 (en) * | 2008-03-21 | 2012-05-08 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| WO2009134668A2 (en) | 2008-05-01 | 2009-11-05 | Merck & Co., Inc. | 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators |
| WO2010019391A1 (en) * | 2008-08-12 | 2010-02-18 | Merck Sharp & Dohme Corp. | N-heterocyclic m1 receptor positive allosteric modulators |
| AU2009302703A1 (en) | 2008-10-06 | 2010-04-15 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| US8436016B2 (en) * | 2008-10-23 | 2013-05-07 | Scott D. Kuduk | Fused heterocyclic M1 receptor positive allosteric modulators |
| CA2750708A1 (en) * | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators |
| US8293744B2 (en) | 2009-04-20 | 2012-10-23 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators |
| EP2483275B1 (en) * | 2009-10-01 | 2014-10-15 | Merck Sharp & Dohme Corp. | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
| EP2501231B1 (en) * | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| PT2512243E (pt) | 2009-12-17 | 2016-06-08 | Merck Sharp & Dohme | Moduladores alostéricos positivos de recetor de quinolina amida m1 |
| WO2011137049A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived m1 receptor positive allosteric modulators |
| EP2582241B1 (en) | 2010-06-15 | 2016-04-06 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| EP2582676B1 (en) * | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| US8697690B2 (en) | 2010-07-01 | 2014-04-15 | Merck Sharp & Dohme Corp. | Isoindolone M1 receptor positive allosteric modulators |
| WO2012158474A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
| WO2012158473A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
| WO2012158475A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked lactam m1 receptor positive allosteric modulators |
| US9586964B2 (en) | 2011-10-28 | 2017-03-07 | Vanderbilt University | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| WO2013071201A1 (en) | 2011-11-11 | 2013-05-16 | Vanderbilt University | Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US9029563B2 (en) | 2012-01-06 | 2015-05-12 | Vanderbilt University | Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors |
| US9012445B2 (en) | 2012-01-12 | 2015-04-21 | Vanderbilt University | Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors |
| WO2013129622A1 (ja) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP2921480B1 (en) | 2012-11-19 | 2017-10-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| CA2987843C (en) | 2015-06-08 | 2020-07-14 | Suven Life Sciences Limited | Muscarinic m1 receptor positive allosteric modulators |
| PE20180252A1 (es) * | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
| AU2016320645B2 (en) | 2015-09-10 | 2019-02-28 | Suven Life Sciences Limited | Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators |
| WO2017155816A1 (en) * | 2016-03-09 | 2017-09-14 | Merck Sharp & Dohme Corp. | Quinazoline compounds useful as m1 receptor positive allosteric modulators |
| US11523858B2 (en) | 2017-08-11 | 2022-12-13 | Bradley D. Vilims | System and method for RF ablation with generated images of ablated tissue lesions |
| CN111018778B (zh) * | 2019-12-30 | 2020-11-06 | 杭州师范大学 | 一种喹诺酮类衍生物及其制备方法和应用 |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1175836A (en) * | 1977-09-20 | 1984-10-09 | Marcel Pesson | Production of 1,4-dihydroquinoline-3-carboxylic acid derivatives |
| JPS5845426B2 (ja) * | 1978-09-29 | 1983-10-08 | 杏林製薬株式会社 | 置換キノリンカルボン酸誘導体 |
| US4914110A (en) * | 1984-05-11 | 1990-04-03 | Societe De Conseils De Recherches Et D'applications Scientifiques | Quinoline derivatives, their preparation and therapeutic compositions containing the same |
| US4623650A (en) * | 1984-12-06 | 1986-11-18 | Pfizer Inc. | Antibiotic derivatives of 7-phenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids |
| JPS61218584A (ja) | 1985-03-23 | 1986-09-29 | Hokuriku Seiyaku Co Ltd | キノリン−３−カルボン酸誘導体 |
| JP2831000B2 (ja) * | 1988-03-03 | 1998-12-02 | 大日本製薬株式会社 | （２−アミノベンゾイル）酢酸エステル誘導体 |
| FR2674247B1 (fr) | 1991-03-19 | 1993-07-16 | Bouchara Sa | Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant. |
| FR2675144B1 (fr) * | 1991-04-10 | 1995-06-16 | Bouchara Sa | Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant. |
| TW301607B (https=) * | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| AU2407997A (en) * | 1996-04-30 | 1997-11-19 | Takeda Chemical Industries Ltd. | Combined use of gnrh agonist and antagonist |
| JP2000103707A (ja) * | 1998-09-28 | 2000-04-11 | Permachem Asia Ltd | 工業用殺菌剤 |
| US6583153B2 (en) * | 2000-12-12 | 2003-06-24 | Ortho-Mcneil Pharmaceutical, Inc. | 7-heterocyclyl quinoline and thieno[2,3-b]yridine derivatives useful as antagonists of gonadotropin releasing hormone |
| DE10108271A1 (de) * | 2001-02-21 | 2002-08-22 | Schering Ag | Chinolin-, Isochinolin- und Phthalazinderivate als Antagonisten des Gonadotropin freisetzenden Hormons |
| SE0101256D0 (sv) * | 2001-04-06 | 2001-04-06 | A & Science Invest Ab | Treatment of low back pain |
| DK1503759T3 (da) * | 2002-05-14 | 2009-04-14 | Univ California | Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| WO2005009971A1 (ja) * | 2003-07-24 | 2005-02-03 | Astellas Pharma Inc. | キノロン誘導体又はその塩 |
| US7498341B2 (en) * | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| EP1730135B1 (en) | 2004-03-10 | 2010-09-22 | The United States of America, represented by the Secretary, Department of Health and Human Services | Qiunolin-4-ones as inhibitors of retroviral integrase for the treatment of hiv, aids and aids related complex (arc) |
| EP1732541A4 (en) * | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
| JP2006117555A (ja) | 2004-10-20 | 2006-05-11 | Kyorin Pharmaceut Co Ltd | １−トリフルオロメチル−４−キノロンカルボン酸誘導体 |
| JP2008094720A (ja) | 2005-01-20 | 2008-04-24 | Astellas Pharma Inc | キノロン誘導体のプロドラッグ又はその塩 |
| JP4858683B2 (ja) | 2005-01-20 | 2012-01-18 | アステラス製薬株式会社 | キノロン誘導体又はその塩の製造法 |
| JP4853824B2 (ja) | 2005-01-20 | 2012-01-11 | アステラス製薬株式会社 | キノロン誘導体を有効成分とする医薬組成物 |
-
2006
- 2006-12-04 AT AT06838942T patent/ATE475650T1/de not_active IP Right Cessation
- 2006-12-04 DE DE602006015851T patent/DE602006015851D1/de active Active
- 2006-12-04 US US11/920,717 patent/US8389545B2/en active Active
- 2006-12-04 EP EP06838942A patent/EP1963271B1/en not_active Ceased
- 2006-12-04 WO PCT/US2006/046262 patent/WO2007067489A1/en not_active Ceased
- 2006-12-04 WO PCT/US2006/046332 patent/WO2007100366A2/en not_active Ceased
- 2006-12-04 JP JP2008543538A patent/JP5192389B2/ja not_active Expired - Fee Related
- 2006-12-04 AU AU2006322045A patent/AU2006322045A1/en not_active Abandoned
- 2006-12-04 CA CA002631917A patent/CA2631917A1/en not_active Abandoned
-
2007
- 2007-04-04 TW TW096112153A patent/TW200840814A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1963271B1 (en) | 2010-07-28 |
| JP5192389B2 (ja) | 2013-05-08 |
| US8389545B2 (en) | 2013-03-05 |
| DE602006015851D1 (de) | 2010-09-09 |
| WO2007067489A1 (en) | 2007-06-14 |
| ATE475650T1 (de) | 2010-08-15 |
| US20100317692A1 (en) | 2010-12-16 |
| WO2007100366A3 (en) | 2007-11-29 |
| CA2631917A1 (en) | 2007-06-14 |
| WO2007100366A2 (en) | 2007-09-07 |
| JP2009518309A (ja) | 2009-05-07 |
| TW200840814A (en) | 2008-10-16 |
| EP1963271A1 (en) | 2008-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1963271B1 (en) | Quinolone m1 receptor positive allosteric modulators | |
| EP2037739B1 (en) | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | |
| EP2483275B1 (en) | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | |
| EP2312949B1 (en) | N-heterocyclic m1 receptor positive allosteric modulators | |
| EP2252151B1 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
| AU2009307892A1 (en) | Fused heterocyclic M1 receptor positive allosteric modulators | |
| EP2212322B1 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
| EP2252299B1 (en) | Fused pyridone m1 receptor positive allosteric modulators | |
| EP2268280B1 (en) | Quinolizidinone M1 receptor positive allosteric modulators | |
| US20110077220A1 (en) | 4-oxo,1-4-dihydroquinoline m1 receptor positive allosteric modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |